Search

Your search keyword '"Drent M"' showing total 845 results
Start Over Author "Drent M"
845 results on '"Drent M"'

1. Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis

Author

Drent, M., Proesmans, V. L. J., Elfferich, M. D. P., Jessurun, N. T., de Jong, S. M. G., Ebner, N. M., and Lewis, E. D. O.

Subjects
Pharmacology, Experimental -- Research -- Health aspects, Gastrointestinal system -- Health aspects -- Research, Sarcoidosis -- Diagnosis -- Care and treatment -- Research, Health
Abstract

Background Clinical manifestations of sarcoidosis vary widely, depending on the intensity of the inflammation and the organ systems affected. So far, no curative treatment exists; the disease can only be suppressed. All treatment options cause side effects affecting quality of life. The aim of this study was to establish and rank the prevalence of self-reported gastrointestinal side effects of drugs used in the treatment of sarcoidosis. Methods A cross-sectional web-based anonymous survey about complaints and side effects was conducted among sarcoidosis patients in the Netherlands, United Kingdom, and United States of America. Results Of the participants, 70% were being treated with one or more drugs. The most important reported side effect was weight gain, associated with increased appetite among prednisone users (as monotherapy as well as in combination with other drugs). Methotrexate (MTX) users especially experienced nausea, with monotherapy as well as combination therapy. Vomiting and weight loss were most prominent among azathioprine and mycophenolate mofetil (MMF) users, whereas diarrhoea was frequently mentioned by MMF and MTX users. The reported side effects of hydroxychloroquine were generally rather mild. Conclusion The current study ranked the gastrointestinal side effects associated with pharmacotherapy in sarcoidosis patients. Pharmacotherapy does have multiple gastrointestinal side effects. The strongest association between a reported side effect and drug use was that of weight gain associated with increased appetite among prednisone users. It would therefore be useful for future research to look further into dietary interventions to counter these side effects and reduce their burden., Author(s): M. Drent [sup.1] [sup.2] [sup.3] , V. L. J. Proesmans [sup.3] [sup.4] , M. D. P. Elfferich [sup.3] , N. T. Jessurun [sup.3] [sup.5] , S. M. G. de [...]

Published
2020
Full Text
View/download PDF

2. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients

Author

Proesmans, V. L. J., Drent, M., Elfferich, M. D. P., Wijnen, P. A. H. M., Jessurun, N. T., and Bast, A.

Subjects
Pulmonary fibrosis -- Diagnosis -- Risk factors, Antifibrinolytic agents -- Complications and side effects, Health
Abstract

Purpose Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive disease, which has a great impact on patients' lives. Pirfenidone and nintedanib are approved and recommended antifibrotic drugs for patients with IPF. The aim of this study was to evaluate self-reported gastrointestinal side effects of antifibrotic drugs in 176 Dutch IPF patients. Methods A cross-sectional web-based anonymous survey about complaints and side effects was conducted among IPF patients in the Netherlands. Logistic regression was used to quantify whether pirfenidone and nintedanib caused complaints of nausea, vomiting, diarrhoea, appetite loss, weight loss or loss of taste or smell perception. Results The questionnaire was completed by 176 IPF patients, 71 of whom used pirfenidone and 85 nintedanib, while 20 patients did not use any antifibrotic drugs. Nintedanib users reported complaints of diarrhoea, vomiting, weight loss and loss of appetite (p < 0.01). Nausea was a significant adverse reaction (p < 0.05). Pirfenidone caused increased appetite loss (p < 0.01) and the risk of weight loss (p < 0.05). The increase in loss of appetite and weight loss did not differ significantly between the two drugs. Conclusion The current study showed that nintedanib causes a significant increase in diarrhoea, vomiting, weight loss and loss of appetite, while pirfenidone led to loss of appetite. Our results suggest new avenues regarding dietary recommendations for IPF patients., Author(s): V. L. J. Proesmans [sup.1] [sup.4] , M. Drent [sup.2] [sup.3] [sup.4] , M. D. P. Elfferich [sup.4] , P. A. H. M. Wijnen [sup.4] [sup.5] , N. T. [...]

Published
2019
Full Text
View/download PDF

3. Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability

Author

Hendriks, C. M. R., Saketkoo, L. A., Elfferich, M. D. P., De Vries, J., Wijnen, P. A. H. M., and Drent, M.

Subjects
Workers -- Health aspects, Work environment -- Health aspects, Sarcoidosis -- Research, Health
Abstract

Objective Sarcoidosis, an inflammatory multi-organ disease with a wide variety of clinical manifestations, affecting people of working age. Patients suffer from a broad spectrum of physical symptoms of varying severity that impact function including cognitive impairment and disabling fatigue. The Dutch Sarcoidosis Society identified a knowledge gap in various facets related to work ability. The aim of this study was to assess sarcoidosis patients' perceived problems related to work performance, employer, and disability evaluations. Methods A cross-sectional web-based anonymous survey was conducted among Dutch sarcoidosis patients recruited through sarcoidosis patient societies and outpatient sarcoidosis clinics. This investigation queried work performance, employer support, and disability evaluations. Results The study sample included 755 patients of whom 43% (n = 328) had undergone disability evaluation and were significantly more likely to experience extrapulmonary symptoms, severe fatigue, reduced exercise capacity along with memory problems and concentration problems with higher mean FAS and SFNSL-scores. Of these 328, 37% (n = 121) perceived they had not been listened to or taken seriously at assessments, and 38% (n = 124) disagreed with the outcome of disability assessments by benefits authorities; 75% (n = 93) appealed or requested re-assessment. Discussion A better understanding of sarcoidosis-related impact on work ability and quantification of disease burden is needed. Education for medical examiners and employers on sarcoidosis may improve quality of assessments and work accommodations. Development of guidelines for benefit authorities, which consider the broad impact of sarcoidosis beyond that of reduced pulmonary function, including extra-pulmonary assessment like fatigue, cognitive difficulties, as well as other organ involvement are needed., Author(s): C. M. R. Hendriks [sup.1] [sup.2] [sup.3] , L. A. Saketkoo [sup.4] [sup.5] [sup.6] , M. D. P. Elfferich [sup.1] , J. De Vries [sup.1] [sup.7] [sup.8] , P. [...]

Published
2019
Full Text
View/download PDF

5. Assessment of Entrustable Professional Activities among Dutch Endocrine Supervisors

Author

Laat, J. M., primary, Horst-Schrivers, A. N.A. van der, additional, Appelman-Dijkstra, N. M., additional, Bisschop, P. H., additional, Dreijerink, K. M.A., additional, Drent, M. L., additional, de Klauw, M. M. van, additional, De Ranitz, W. L., additional, Stades, A. M.E., additional, Stikkelbroeck, N. M.M.L., additional, Timmers, H. J.L.M., additional, and Cate, O. ten, additional

Published
2023
Full Text
View/download PDF

13. The role of ageing in pulmonary disease

Author

Bast, A., Drent, M., FSE Campus Venlo, RS: FSE UCV Adaptive responses in relation to health effect and safety of nutrition, RS: NUTRIM - R3 - Respiratory & Age-related Health, Farmacologie en Toxicologie, and Faculteit FHML Centraal

Subjects
SARCOIDOSIS
Published
2022

15. Barriers and facilitators for systematically registering adverse drug reactions in electronic health records: a qualitative study with Dutch healthcare professionals

Author

Geeven, I., Jessurun, N.T., Wasylewicz, A.T.M., Drent, M, Spuls, P.I., Hoentjen, F., Puijenbroek, E.P. van, Vonkeman, H.E., Grootens, K.P., Doorn, M.B.A. van, Bemt, B.J.F van den, Bekker, C.L., Geeven, I., Jessurun, N.T., Wasylewicz, A.T.M., Drent, M, Spuls, P.I., Hoentjen, F., Puijenbroek, E.P. van, Vonkeman, H.E., Grootens, K.P., Doorn, M.B.A. van, Bemt, B.J.F van den, and Bekker, C.L.

Abstract

Contains fulltext : 251159.pdf (Publisher’s version ) (Open Access), BACKGROUND: Systematically registering ADRs in electronic health records (EHRs) likely contribute to patient safety as it enables the exchange of drug safety data. Currently, ADRs registrations by healthcare professionals (HCPs) is suboptimal. This study aimed to identify barriers and facilitators perceived by HCPs to register ADRs systematically in EHRs. RESEARCH DESIGN AND METHODS: A qualitative study with individual interviews was conducted among specialist physicians and hospital pharmacists from 10 different Dutch hospitals. A semi-structured interview guide was used to identify experienced barriers and facilitators for systematically registering ADRs. Data was analyzed following thematic analysis. Themes within barriers and facilitators were aligned with the Capability-Opportunity-Motivation-Behavior (COM-B) framework. RESULTS: In total, 16 HCPs were interviewed. Identified barriers were: lack of knowledge to recognize ADRs, time constraints, inadequate IT system, lack of support, stuck in routine, and not recognizing the importance of registering ADRs. Identified facilitators were: enhanced knowledge and awareness of ADRs, functional IT systems, expanding accountability for registration, and motivation toward registering. CONCLUSIONS: Barriers and facilitators for registering spanned all aspects of the COM-B model and occurred in individual, social and environmental domains. Addressing these aspects could improve the registration of ADRs and may contribute to patient safety.

Published
2022

16. Corrigendum to “Escaping the niche market: An innovation system analysis of the Dutch building integrated photovoltaics (BIPV) sector” [Renew Sustain Energy Rev 155 (2022) 111912]

Author

Dynamics of Innovation Systems, Integration of Photovoltaic Solar Energy, Innovation Studies, Energy and Resources, Vroon, T., Teunissen, E., Drent, M., Negro, S., van Sark, W. G.J.H.M., Dynamics of Innovation Systems, Integration of Photovoltaic Solar Energy, Innovation Studies, Energy and Resources, Vroon, T., Teunissen, E., Drent, M., Negro, S., and van Sark, W. G.J.H.M.

Published
2022

28. Sarcoidosis

Author

Grutters, J.C., primary, Drent, M., additional, and van Den Bosch, J.M.M., additional

Published
2009
Full Text
View/download PDF

29. Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good

Author

Wells, Athol U, Behr, Juergen, Costabel, Ulrich, Cottin, Vincent, Poletti, Venerino, Richeldi, Luca, Albera, C, Ancochea, J, Antoniou, KM, Bonella, F, Bonniaud, P, Bouros, D, Bresser, P, Cordier, JF, Crestani, B, Domagala-Kulawik, J, Drent, M, Egan, JJ, Geiser, T, Grunewald, J, Grutters, J, Gudmundsson, G, Guenther, A, Harari, S, Harrison, NK, Hirani, N, Hodgson, U, Kahler, CM, Keane, MP, Kiter, G, Kneussl, M, Maher, TM, Mogulkoc, N, Muller-Quernheim, J, Neurohr, C, Nunes, H, Parfrey, H, Peros-Golubicic, T, Polychronopoulos, V, Prevot, G, Renzoni, ER, Robalo Cordeiro, C, Saltini, C, Skold, M, Spagnolo, P, Thomeer, M, Tomasseti, S, Valeyre, D, Vancheri, C, Wallaert, B, Wuyts, W, and Xaubet, A

Published
2012
Full Text
View/download PDF

41. When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic

Author

Sweiss, N. J., Korsten, P., Syed, H. J., Syed, A., Baughman, R. P., Yee, A. M. F., Culver, D. A., Sosenko, T., Azuma, A., Bonella, F., Costabel, U., Drake, W. P., Drent, M., Lower, E. E., Israel-Biet, D., Mostard, R. L. M., Nunes, H., Rottoli, P., Spagnolo, P., Wells, A. U., Wuyts, W. A., and Judson, M. A.

Subjects
SARS, immunosuppressives, Sarcoidosis, SARS-CoV-2, COVID-19, Disease Management, severe acute respiratory syndrome, Pneumonia, diffuse lung disease, Betacoronavirus, coronavirus disease, sarcoidosis, Coronavirus Infections, Humans, Pneumonia, Viral, Pandemics, Viral
Published
2020

42. Free Papers

Author

Emmanuel, G., Carranza, S., Vettichira, S., Paradis, M., Lie, T., Kessler, P., Schini-Kerth, V. B., Koh, Y., Hybertson, B. M., Jepson, E. K., Kim, M. J., Lee, I., Lim, C. M., Lee, S. D., Kim, W. S., Kim, D. S., Kim, W. D., Repine, J. E., Takeda, T., Yukioka, T., Matsuda, H., Shimazaki, S., Kammermeier, D., Birkmann, J., Blinzler, L., Gallmeier, W. M., Heuser, D., Jourdain, M., Mangalaboyi, J., Carrette, O., Toumoys, A., Fourrier, F., Mizon, J., Chopin, C., Peake, S. L., Carter, J. K., Russ, R. G., Pierides, J., Leppard, J. P., Porter, K., Galley, H. F., Webster, N. R., Wigmore, S. J., Walsh, T. S., Hopton, P., Lee, A., Ross, J. A., Majcherczyk, P. A., Pugin, J., Glauser, M. P., Heumann, D., Zanetti, G., de Werra, I., Sablotzki, A., Welters, I., Menges, T., Görlach, G., Lehmann, N., Hempelmann, G., Giannitsis, E., Tettenborn, I., Stierle, U., Dalhoff, K., Sheikhzadeh, A., Diederich, K. W., Gant, V., Maciver, C., Treacher, D. F., Lamy, M., Thijs, L. G., Eisele, B., Keinecke, H. -O., Schuster, H. P., Matthias, F. R., Oettinger, W., Hartenauer, U., Fourrier, F., Delvos, U., Stott, S. A., Noble, D. W., Schobersberger, W., Hoffmann, G., Fandrey, J., Bellingan, G. J., Caldwell, H., Dransfield, I., Howie, S. M., Haslett, C., Liaudet, L., Feihl, F., Markert, M., Perret, C., Williams, M. A., Rhoades, C., White, S. A., Miller, J., Withington, S., Newland, A. C., Kelsey, S. M., Froon, A., Bonten, M., Gaillard, C., Greve, J., de Leeuw, P., Drent, M., Stobberingh, E., Buurman, W., Fourcade, O., Simon, M. -F., Leballe, F., Ashraf, R., Sarda, L., Cathala, B., Chap, H., Reper, P., Danckaert, R., Jeunen, R., Bruyns, T., De Hemptinne, J., and Vanderkelen, A.

Published
1996
Full Text
View/download PDF

47. Multiple organ dysfunction syndrome (MODS) after an intravenous injection of lamp oil (liquid paraffin)

Author

Houben, M. H. M. G., Drent, M., Jacobs, J. A., Schrey, G., and Ramsay, G.

Subjects
Intensive care nursing -- Research, Multiple organ failure -- Risk factors, Health care industry
Abstract

Byline: M. H. M. G. Houben (1), M. Drent (2), J. A. Jacobs (3), G. Schrey (1), G. Ramsay (4) Author Affiliation: (1) Department of Internal Medicine, University Hospital, Maastricht, The Netherlands, NL (2) Department of Pulmonology, University Hospital, Maastricht, The Netherlands, NL (3) Department of Medical Microbiology, University Hospital, Maastricht, The Netherlands, NL (4) Department of Surgery, University Hospital, Maastricht, The Netherlands, NL Article note: Received: 23 June 1997 Accepted: 6 November 1997

Published
1998

Catalog

Books, media, physical & digital resources
See catalog results